A key committee of the US Senate has given its stamp of approval for the BIOSECURE Act, which aims to prevent contracts with Chinese biotech companies. 7 March 2024
President Joe Biden’s actions to cut prescription drug prices through the Inflation Reduction Act (IRA) and other means have been far from popular with big phar 7 March 2024
All manufacturers participating in the first cycle of Medicare drug price negotiations have responded with counter offers, according to the US Department of Hea 5 March 2024
Drugmakers, patient advocate groups, policymakers and others have come together for Rare Disease Day, which took place at the end of February, to both celebrate 4 March 2024
Reform of the procurement policies applied to generic medicines is needed to ensure greater security of supply for patients and health systems, according to Med 19 February 2024
US trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) has made clear its opposition to the drug price-setting provisions in the Biden 14 February 2024
Non-governmental organization Médecins Sans Frontières (MSF) has issued a warning about the details of a trade deal that is about to be agreed by India and the 14 February 2024
In the USA, the House of Representatives have voted overwhelmingly in favor of legislation which would restore the ability of drugmakers to fully expense R&D co 5 February 2024
US healthcare lobbyist Vital Transformation has released a document outlining objections to the expansion drug pricing policies under the Inflation Reduction Ac 19 January 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.